martes, 25 de abril de 2023

The majority of Dutch patients with type 2 diabetes at high cardiovascular risk are not receiving recommended SGLT2 inhibitors.

The majority of Dutch patients with type 2 diabetes at high cardiovascular risk are not receiving recommended SGLT2 inhibitors.

No hay comentarios:

Publicar un comentario